{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.2","value":"7.69"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"title":"Irinotecan: Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21","value":"13.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"title":"SN-38: Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"66.8","value":"5.04"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"title":"Irinotecan: Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"138","value":"7.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"SN-38: Cycle 1 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"t1/2 was the time measured for the drug concentration to decrease by one half. t1/2 was determined by Loge (2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. SN-38 is a metabolite of Irinotecan.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received encorafenib 300 milligrams (mg) once daily (QD) orally (received after Cycle 1 Day 3) and cetuximab 500 mg per square meters (mg/m\\^2) intravenous (IV) infusion for 120 minutes once every 2 weeks (Q2W) along with fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and irinotecan 180 mg/m\\^2 as IV infusion for 90 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG000","title":"SLI: Cohort 1 [EC + FOLFIRI]"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK parameter analysis set was analyzed. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure. Here, \"Number Analyzed\" signifies participants evaluable at specified timepoints. Participants received irinotecan in Cohort 1 of SLI, hence data is reported only for Cohort 1 and not for Cohort 2.","reportingStatus":"POSTED","timeFrame":"Cohort 1: Pre-dose (0 hr), 0.75, 1.5, 2.5, 3.5, 5.5, 7.5, and 48 hrs post-dose on Days 1 and 15 of Cycle 1","title":"SLI, Cohort 1: Apparent Terminal Elimination Half-Life (t1/2) of Irinotecan and Its Metabolite SN-38","type":"SECONDARY","unitOfMeasure":"Hours"}